Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder

Table 1 Trial schedule of patients and healthy controls

Visit (V)/Action	SC	BL	V1	V2	V3	V4	V5	V6	V7	V8
Trial day	-14-0	0	7 ± 2	14 ± 2	21 ± 2	28 ± 2	35 ± 2	42 ± 2	49 ± 2	56 ± 2
Prescreening
DIA-X-SSQ ¹⁾	X
Basic documentation
Inclusion/exclusion criteria		X
Patient information and consent		X
Demographics		X
Medical history		X
Diagnostic procedures
M.I.N.I. SCID-II	X²⁾ X	X³⁾ X
Treatment outcome
HAMD-17 IDS-C30 IDS-SR30 SF-12		X	X	X	X	X	X	X	X	X
Peripheral blood
Serum		X	X	X	X	X	X	X	X	X
Plasma		X	X	X	X	X	X	X	X	X
Whole blood (EDTA)		X	X	X	X	X	X	X	X	X
Neuropsychology
MWT		X
RWT		X		X		X		X		X
TMT A/B		X		X		X		X		X
RWT (category change)		X		X						X
DOT		X		X						X
RFFT		X		X						X
End of trial										X

1) only in healthy controls; 2) in patients at screening visit; 3) in healthy controls at baseline visit; SC = Screening; BL = Baseline; V1 = Visit 1, V2 = Visit 2, V3 = Visit 3, V4 = Visit 4, V5 = Visit 5, V6 = Visit 6, V7 = Visit 7, V8 = Visit 8; DIA-X-SSQ = Screening Questionnaire of the DIA-X-Interview, M.I.N.I. = MINI International Neuropsychiatric Interview; SCID-II = Structured Clinical Interview for DSM-IV Axis II Personality Disorders; HAMD17 = Hamilton Depression Rating Scale; IDS-C30 = Inventory of Depressive Symptoms - Interview, IDS-SR30 = Inventory of Depressive Symptoms - Self rating, MWT = Multiple Vocabulary Test, TMT = Trail Making Test, DOT = Adaptive Digit Ordering Test, RFFT = Ruff Figural Fluency Test

ISSN: 1471-244X